Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-18T02:51:38.227Z Has data issue: false hasContentIssue false

Bony Metastases of Anaplastic Oligodendroglioma Respond to Temozolomide

Published online by Cambridge University Press:  02 December 2014

Tara Morrison
Affiliation:
Division of Neurology, Crolla Family Brain Tumour Research Unit, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Juan M. Bilbao
Affiliation:
Division of Neuropathology, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Guisheng Yang
Affiliation:
Division of Neuropathology, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
James R. Perry
Affiliation:
Division of Neurology, Crolla Family Brain Tumour Research Unit, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Fewer than 30 cases of oligodendroglioma or anaplastic oligodendroglioma metastatic to bone are reported in the literature. Prolonged survival even with therapy is uncommon.

Methods:

We report a case of anaplastic oligodendroglioma metastatic to bone with a dramatic and durable response to temozolomide therapy. A retrospective case review, molecular analysis, and literature search were performed.

Results:

The patient presented with a right frontal mass in 1990. Progression led to resection of the lesion in 1995. Histology revealed an anaplastic oligodendroglioma and the tumour was found to have allelic loss of heterozygosity (LOH) of chromosome 1p (1p-). He received standard radiation therapy. In 2000 he developed hip and pelvic pain. A bone scan showed multiple skeletal lesions. Magnetic resonance imaging of the brain showed stability of intracranial disease. Resection of one lesion found metastatic anaplastic oligodendroglioma with identical morphology to the patient’s original tumour, including glial fibrillary acidic protein expression. The patient was started on standard temozolomide chemotherapy and celecoxib with prompt pain relief, and rapid normalization of serum alkaline phosphatase. He received a total of 12 cycles of combined therapy with no toxicity and no evidence of progression until increasing pain marked disease recurrence. The patient underwent palliative chemo- and radiation therapy but eventually succumbed.

Discussion:

Loss of heterozygosity 1p- is associated with prolonged survival in anaplastic oligodendroglioma and may increase the cumulative risk for development of systemic metastases. We speculate that metastases from oligodendroglioma harbouring loss of heterozygosity at chromosome 1p- retain the chemosensitivity of the initial lesion.

Type
Case Report
Copyright
Copyright © The Canadian Journal of Neurological 2004

References

1.Kraus, JA, Koopmann, J, Kaskel, Pet al.Shared allelic losses onchromosomes 1p an 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropath Exp Neurol 1995; 54(1): 9199.CrossRefGoogle ScholarPubMed
2.Louis, DN, von Deiming, A, Seizinger, BR.A (CA)n Dinucleotiderepeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Path 1992; 141(4):777782.Google Scholar
3.Weber, JL, May, PE.Abundant class of human DNA polymophismswhich can be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44(3):388396.Google Scholar
4.Weber, JL, May, PE.Dinucleotide repeat polymorphism at theD10S89 locus. Nucl Acid Res 1990; 18(16): 4637.CrossRefGoogle ScholarPubMed
5.Litt, M, Luty, JA.A hypervariable microsatellite revealed by in vitroamplification of a dinucleotide repeat within the cardiac muscle actin gene. Am J Hum Genet 1989; 44(3):397401.Google Scholar
6.Burmelster, M,Cox, DR, Myers, RM.Dinucleotide repeatpolymorphism located at D21S120. Nucl Acid Res 1990; 18(16): 4969.Google Scholar
7.Cairncross, JG, Ueke, K, Zlatescu, MC, et al.Specific geneticpredictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90(19): 14731479.Google Scholar
8.Spataro, J, Sacks, O.Oligodendroglioma with remote metastases. JNeurosurg 1968; 28(4): 373379.Google Scholar
9.Macdonald, DR, O’Brien, RA, Gilbert, JJ, Cairncross, JG.Metastaticanaplastic oligodendroglioma. Neurology 1989; 39: 15931596.CrossRefGoogle ScholarPubMed
10.Ordóñez, NG, Ayala, AA, Leavens, ME.Extracranial metastases ofoligodendroglioma: report of a case and review of the literature. Neurosurgery 1981; 8(3):391395 (comments 395-396).Google Scholar
11.Giordana, MT, Gasverde, S, Balteri, I, et al.Bone metastasis ofoligodendrogliomas: clinical and molecular genetic study. Neuro-Oncology 2002; 4:S38e (Abstract).Google Scholar
12.Van den Bent, MJ, Keime-Guibert, F, Brandes, AA, et al.Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001; 57(2):340342.Google Scholar
13.Chinot, OL, Honore, S, Dufour, H, et al.Safety and efficacy oftemozolomide in patients with recurrent anaplastic oligodendrogliomasafterstandardradiotherapy andchemotherapy. J Clin Oncol 2001; 19(9): 24492455.Google Scholar
14.Deininger, MH, Weller, M, Streffer, J, Mittelbronn, M, Meyermann, R.Patterns of cyclooxygenase-1 and -2 expression in humangliomas in vivo. Acta Neuropathol (Berl) 1999; 98(3):240244.Google Scholar
15.Phillips, RK, Wallace, MH, Lynch, PM, et al, FAP Study Group. Arandomised, double blind, placebo controlled study of celecoxib a selective cyclooxygenase-2 inhibitor on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50(6):857860.Google Scholar
16.James, TGI, Pagel, W.Oligodendroglioma with extracranialmetastases. Br J Surg 1951; 39:5665.Google Scholar
17.Jellinger, K, Minauf, M, Salzer-Kuntschik, M.Oligodendrogliomawith extraneural metastases. J Neurol Neurosurg Psychiatr 1969;32:249253.Google Scholar
18.Schuster, H, Jellinger, K, Gund, A, Regele, H.Extracranial metastasesof anaplastic cerebral gliomas. Acta Neurochirugica 1976;35:247259.CrossRefGoogle Scholar
19.Smith, DR, Hardman, JM, Earle, KM.Metastasizing neuroectodermaltumors of the central nervous system. J Neurosurg 1969; 31:5058.Google Scholar
20.Eade, OE, Urich, H.Metastasizing gliomas in young subjects. JPathol 1971; 103:245256.CrossRefGoogle ScholarPubMed
21.Kernohan, JW.Oligodendrogliomas. In: Minckler, J. (Ed) Pathologyof the Nervous System. New York, McGraw-Hill Co, vol. 2, 1971:19932007.Google Scholar
22.Cappelaere, P, Clay, A, Adenis, L, Demaille, A, Laine, E.Lesm⃩tastases des tumeurs cérébrales primitives endehors du névraxe: a propos de trois observations. Bull Cancer (Paris) 1972;59:235254.Google Scholar
23.Brander, WL, Turner, DR.Extracranial metastases from a glioma inthe absence of surgical intervention. J Neurol Neurosurg Psychiatry 1975; 38:11331135.Google Scholar
24.Chin, HW, Hazel, JJ, Kim, TH, Webster, JH.Oligodendrogliomas: I. Aclinical study of cerebral oligodendrogliomas. Cancer 1980; 45:14581466.Google Scholar
25.Newman, HFV, Howard, GCW, Reid, PM.Metastaticoligodendroglioma presenting as a leukoerythroblastic anemia. Eur J Surg Onc 1985; 11: 287288.Google Scholar
26.Gerrard, GE, Bond, MG, Jack, AS.Bone marrow infiltration by aparietal lobe grade III oligodendroglioma. Clin Oncol 1995;7:321322.CrossRefGoogle ScholarPubMed
27.Monzani, V, Rovellini, A, Masini, B, Cappricci, E, Miserocchi, G.Metastatic oligodendroglioma. Case report. J Neurol Sci 1996;40(3-4):239241.Google ScholarPubMed
28.Dawson, TP. Case report. Pancytopenia from a disseminatedanaplastic oligodendroglioma. Neuropathol App Neurobiol 1997; 23:516520.Google Scholar
29.Finsterer, J, Breiteneder, S, Mueller, MR, et al.Pleural and bonemarrow metastasis from supratentorial oligoastrocytoma gradeIII. Oncology 1998; 55:345348.Google Scholar